NAPWA, TAEP to Urge Congress to Implement Healthcare Reform, End Federal Bans Targeting HIV-Positive Americans at AIDSWatch 2012
April 19, 2012 08:00 ET
|
National Association of People with AIDS
WASHINGTON, DC--(Marketwire - Apr 19, 2012) - Today the National Association of People with AIDS (NAPWA) and the Treatment Access Expansion Project (TAEP) announces AIDSWatch 2012, the largest...
VIRxSYS Issued U.S. Patents for Its Lentiviral Vector and SMaRT RNA Platforms
November 15, 2011 09:10 ET
|
VIRxSYS Corporation
GAITHERSBURG, MD--(Marketwire - Nov 15, 2011) - VIRxSYS Corporation, a Maryland-based biotechnology company, today announced that the United States Patent and Trademark Office has issued two...
New HIV Research Findings to Be Presented at NAPWA "Treatment Horizons: Pathways to a Functional Cure" Satellite Symposium, International AIDS Society, Rome
July 15, 2011 07:30 ET
|
National Association of People with AIDS
SILVER SPRING, MD and ROME--(Marketwire - Jul 15, 2011) - HIV researchers working towards developing potential functional cures from three continents will present new data that collectively light a...
"Next Generation" HIV/AIDS Treatments Featured in NAPWA and The AIDS Institute's Community Forum at XVIII International AIDS Conference
July 22, 2010 11:07 ET
|
National Association of People with AIDS
VIENNA, AUSTRIA--(Marketwire - July 22, 2010) - New data presented by researchers at the XVIII International AIDS Conference this week shows significant momentum for the emerging field of...
"Research Advances from Therapeutic HIV Vaccines and Other Immune-Based Therapies" to Be Showcased at NAPWA Sponsored Community Treatment Research Forum at XVIII World AIDS Conference
July 13, 2010 13:45 ET
|
National Association of People with AIDS
SILVER SPRING, MD--(Marketwire - July 13, 2010) - The National Association of People with AIDS today announced that it is hosting a Community Treatment Research Forum, "Research Advances from...
GlobeImmune's Hepatitis C Product Candidate Improves End of Treatment Response in All IL-28 B Genotypes, With the Greatest Effect in the Hardest-to-Treat Patients
April 19, 2010 07:00 ET
|
GlobeImmune
LOUISVILLE, CO--(Marketwire - April 19, 2010) - GlobeImmune Inc. announced Phase 2b data for GI-5005, the Company's investigational Tarmogen® product for hepatitis C virus (HCV) infection,...
GlobeImmune GI-5005 HCV Product Candidate Improves Sustained Virologic Response by 10 Percent, Demonstrating Potential to Be First Therapeutic Vaccine for HCV
April 15, 2010 13:00 ET
|
GlobeImmune
LOUISVILLE, CO--(Marketwire - April 15, 2010) - GlobeImmune, Inc. today announced final Phase 2b data for GI-5005, the Company's investigational Tarmogen® product candidate, demonstrating...